Ramucirumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Biliary Tract Cancer · Phase 2 · investigational in the US

Also approved (3)
CA
  • CYRAMZA® (ramucirumab) is indicated for: • Gastric Cancer – CYRAMZA (ramucirumab) as a single agent or in combination with paclitaxel is indicated for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior platinum and fluoropyrimidine chemotherapy.
Product first approved 2015Health Canada
JP
  • Treatment of unresectable advanced or recurrent gastric cancer
Product first approved 2015PMDA
EU
  • Gastric/GEJ adenocarcinoma first; EPAR now also lists metastatic colorectal cancer, NSCLC, hepatocellular carcinoma
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (16)
Advanced Metastatic Colorectal Cancer
NCT03520946 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2019-01-24 – 2024-07-30 · Colorectal Cancer
What this study did
Gastric Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07763171 · Gruppo Oncologico del Nord-Ovest
2026-09-01 – 2031-09 · Gastroesophageal Adenocarcinoma
What this study did
NCT04675983 · Innovent Biologics (Suzhou) Co. Ltd.
2021-03-10 – 2023-02-12 · Gastric Adenocarcinoma
What this study did
NCT02934464 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2016-12 – 2021-12 · Stomach Neoplasms
What this study did
NCT02898077 · Eli Lilly and Company
2017-03-02 – 2021-04-12 · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
What this study did
NCT02314117 · Eli Lilly and Company
2015-01-20 – 2020-08-14 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2/3 (5)
Gastric Cancer
NCT06203600 · National Cancer Institute (NCI)
2024-06-24 – 2027-10-31 · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05002127 · ALX Oncology Inc.
2022-01-15 – 2026-06-30 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
What this study did
NCT03081143 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2017-05-10 – 2026-05-04 · Advanced Gastric or EGJ Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06616584 · SWOG Cancer Research Network
2025-05-22 – 2028-12-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT02661971 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2016-06 – 2022-06-20 · Stomach Cancer, Gastroesophageal Junction Cancer
What this study did
Phase 2 (81)
Biliary Tract Cancer
Colorectal Cancer
NCT01111604 · Eli Lilly and Company
2010-08 – 2013-12 · Colon Cancer, Rectal Cancer
What this study did
NCT00862784 · Eli Lilly and Company
2009-04 – 2011-08 · Colorectal Carcinoma
What this study did
Gastric Cancer
NCT06962137 · Universitaire Ziekenhuizen KU Leuven
2025-12-11 – 2030-08-30 · Gastric Cancer Adenocarcinoma Metastatic, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07669740 · The First Affiliated Hospital with Nanjing Medical University
2026-07-01 – 2028-12-30 · Gastric Cancer (Diagnosis)
What this study did
NCT04069273 · Harry H Yoon
2020-12-01 – 2027-12-10 · Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
What this study did
NCT06038578 · Toray Industries, Inc
2023-10-04 – 2027-10-31 · Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06251973 · Memorial Sloan Kettering Cancer Center
2024-02-01 – 2027-08-01 · Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Cancer, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Esophageal Cancer, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT02678182 · Royal Marsden NHS Foundation Trust
2015-02 – 2027-06 · Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
What this study did
NCT04660760 · Academic and Community Cancer Research United
2021-06-16 – 2026-11-30 · Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
What this study did
NCT06564298 · The First Affiliated Hospital with Nanjing Medical University
2024-08 – 2026-06 · Stomach Neoplasms
What this study did
NCT04632459 · Samsung Medical Center
2021-06-16 – 2025-01-15 · Gastric Cancer
What this study did
NCT05942573 · Tianjin Medical University Cancer Institute and Hospital
2022-12-24 – 2024-12-31 · Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
What this study did
NCT03760822 · Federation Francophone de Cancerologie Digestive
2018-11-16 – 2024-12 · Stomach Cancer, Stomach Neoplasm, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05071053 · Sanofi
2021-11-16 – 2024-11-05 · Adenocarcinoma Gastric, Gastrooesophageal Cancer
What this study did
NCT03686488 · H. Lee Moffitt Cancer Center and Research Institute
2018-12-20 – 2024-05-31 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
What this study did
NCT05311176 · Imugene Limited
2022-08-17 – 2024-04-04 · Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma, Stomach Cancer, Stomach Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05190445 · Pieris Pharmaceuticals, Inc.
2021-11-01 – 2023-02-01 · HER2-positive Gastric Cancer
What this study did
NCT03766607 · Korean South West Oncology Group
2019-09-30 – 2022-06-30 · Gastric Cancer
What this study did
NCT02726399 · Memorial Sloan Kettering Cancer Center
2016-03-18 – 2019-02-26 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT02514551 · Eli Lilly and Company
2015-10-12 – 2018-12-28 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT01983878 · Eli Lilly and Company
2013-12 – 2016-02 · Gastric Cancer
What this study did
Hepatocellular Carcinoma
NCT06441019 · Fudan University
2024-07-01 – 2026-05-31 · Hepatocellular Carcinoma,Bispecific Antibodies, HAIC, Ramucirumab
What this study did
NCT01246986 · Eli Lilly and Company
2011-03-30 – 2019-12-24 · Carcinoma, Hepatocellular
What this study did
NCT00627042 · Eli Lilly and Company
2008-02 – 2011-05 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04340882 · Emory University
2020-06-05 – 2030-09-30 · Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT07098338 · AstraZeneca
2025-08-07 – 2029-04-06 · Non-Small Cell Lung Cancer
What this study did
NCT05642572 · SWOG Cancer Research Network
2023-05-05 – 2028-06-30 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT06031688 · SWOG Cancer Research Network
2024-08-08 – 2028-05-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT04040361 · National Cancer Center Hospital East
2019-11-30 – 2027-12-31 · Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA
What this study did
NCT06448754 · AstraZeneca
2024-08-27 – 2027-07-30 · Non-small Cell Lung Cancer
What this study did
NCT04332367 · Abramson Cancer Center at Penn Medicine
2020-08-01 – 2027-06-01 · Non-small Cell Lung Cancer
What this study did
NCT03527108 · Fox Chase Cancer Center
2020-10-08 – 2027-04 · Non Small Cell Lung Cancer
What this study did
NCT03909334 · Xiuning Le
2019-07-25 – 2027-01 · Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
What this study did
NCT05007769 · Washington University School of Medicine
2021-10-31 – 2026-04-30 · Non-small Cell Lung Cancer, Non-small Cell Carcinoma, NSCLC, Non Small Cell Lung Cancer
What this study did
NCT04394624 · Sanofi
2020-08-31 – 2024-10-24 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT03689855 · Washington University School of Medicine
2019-06-05 – 2024-04-22 · Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC
What this study did
NCT03971474 · SWOG Cancer Research Network
2019-05-28 – 2024-01-01 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04120454 · Ohio State University Comprehensive Cancer Center
2020-06-17 – 2023-08-19 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03904108 · ROGER S KERESZTES MD
2019-06-27 – 2020-07-27 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02730247 · Liza Villaruz, MD
2017-07-05 – 2019-09-08 · Non-small Cell Lung Cancer
What this study did
NCT02831491 · Eli Lilly and Company
2016-11 – 2018-01 · Stage IV Non-small Cell Lung Cancer
What this study did
NCT01703091 · Eli Lilly and Company
2012-12 – 2016-07 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT00735696 · Eli Lilly and Company
2009-01 – 2012-01 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05980000 · Washington University School of Medicine
2023-10-27 – 2030-06-30 · Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC
What this study did
NCT07546812 · Gilead Sciences
2026-08-07 – 2030-01 · HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
What this study did
NCT04205968 · SWOG Cancer Research Network
2020-06-01 – 2027-08-01 · Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
What this study did
NCT06043427 · Canadian Cancer Trials Group
2024-04-16 – 2027-07-31 · Gastroesophageal Adenocarcinoma
What this study did
Phase 1/2 (19)
Gastric Cancer
NCT05927857 · National Health Research Institutes, Taiwan
2024-04-01 – 2028-12-31 · Metastatic Gastric Adenocarcinoma, Second Line, Chemotherapy
What this study did
NCT05894824 · Yonsei University
2024-02-05 – 2026-01-01 · Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer
What this study did
NCT03008278 · National Cancer Institute (NCI)
2018-02-06 – 2025-08-13 · Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03739801 · University of Southern California
2020-04-06 – 2023-04-06 · Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04888663 · Yonsei University
2018-02-13 – 2021-09-02 · Recurrent/Metastatic Gastric Cancer
What this study did
NCT02999295 · National Cancer Center, Japan
2017-01 – 2019-08 · Gastric Cancer, Gastroesophageal Junction Region (GEJ) Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06996782 · AstraZeneca
2025-11-24 – 2029-02-23 · Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT06007937 · Memorial Sloan Kettering Cancer Center
2023-08-17 – 2028-08-17 · Non Small Cell Lung Cancer, Metastatic, Recurrent
What this study did
NCT04151563 · Bristol-Myers Squibb
2021-04-15 – 2026-05-13 · Carcinoma, Non-small Cell Lung Cancer
What this study did
NCT02082210 · Eli Lilly and Company
2014-03-07 – 2018-01-24 · Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06445972 · Merck Sharp & Dohme LLC
2024-08-07 – 2030-08-08 · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
What this study did
NCT06771622 · FBD Biologics Limited
2025-03-13 – 2029-01-01 · Solid Cancer
What this study did
NCT03650764 · Washington University School of Medicine
2019-05-29 – 2026-05-11 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04145349 · Eli Lilly and Company
2020-01-22 – 2026-01-23 · Desmoplastic Small Round Cell Tumor
What this study did
NCT04921904 · Baylor Research Institute
2021-06-11 – 2025-08-14 · Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03995017 · University of Kansas Medical Center
2020-01-09 – 2024-12 · Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma
What this study did
NCT03745430 · Hellenic Cooperative Oncology Group
2019-01-29 – 2023-04-23 · Pancreatic Adenocarcinoma
What this study did
NCT04145700 · Eli Lilly and Company
2020-03-04 – 2023-02-23 · Synovial Sarcoma
What this study did
NCT04604132 · Basilea Pharmaceutica
2020-10-06 – 2022-11-21 · Gastric Adenocarcinoma
What this study did
Phase 1 (34)
Colorectal Cancer
NCT03872947 · Toray Industries, Inc
2019-04-26 – 2026-07-16 · Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT03798626 · Novartis Pharmaceuticals
2019-05-22 – 2025-02-05 · Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
What this study did
NCT02745769 · Eli Lilly and Company
2016-10-21 – 2019-01-22 · Advanced Cancer, Colorectal Cancer, Mantle Cell Lymphoma
What this study did
Gastric Cancer
NCT07594548 · Northwestern University
2026-11-10 – 2031-09-09 · Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Carcinoma
What this study did
NCT06675136 · City of Hope Medical Center
2025-10-29 – 2029-01-14 · Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
What this study did
NCT02970539 · Athenex, Inc.
2016-12-08 – 2022-12-31 · Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer
What this study did
Hepatocellular Carcinoma
NCT05856864 · Tianjin Medical University Cancer Institute and Hospital
2024-06-01 – 2025-05-01 · Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
What this study did
NCT02069041 · Eli Lilly and Company
2014-04 – 2016-09 · Carcinoma, Hepatocellular
What this study did
Non-Small Cell Lung Cancer
NCT04999761 · Taiho Pharmaceutical Co., Ltd.
2021-06-01 – 2027-06 · Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer, Biliary Tract Cancer
What this study did
NCT02789345 · Eli Lilly and Company
2016-10-24 – 2022-05-09 · Non-small Cell Lung Cancer
What this study did
NCT02443324 · Eli Lilly and Company
2015-07-29 – 2022-04-12 · Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer
What this study did
NCT02572687 · Eli Lilly and Company
2016-02-19 – 2021-01-13 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
What this study did
NCT05800418 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2019-11-04 – 2020-02-18 · Gastric Cancer, Non-small Cell Lung Cancer, Colo-rectal Cancer
What this study did
NCT02079636 · Eli Lilly and Company
2014-03-28 – 2019-08-29 · Carcinoma, Non-small Cell Lung
What this study did
Other / comorbidity
NCT05719558 · Astellas Pharma Global Development, Inc.
2023-03-13 – 2030-05-31 · Advanced Solid Tumors
What this study did
NCT05365581 · Astellas Pharma Global Development, Inc.
2022-06-07 – 2028-05-31 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
What this study did
NCT03013218 · ALX Oncology Inc.
2017-02-03 – 2025-07-08 · Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma
What this study did
NCT05980416 · Elevation Oncology
2023-08-10 – 2025-06-02 · Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
What this study did
NCT02791334 · Eli Lilly and Company
2016-06-29 – 2024-06-27 · Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
What this study did
NCT04557384 · Eli Lilly and Company
2021-02-23 – 2021-05-25 · Advanced Solid Tumor
What this study did
NCT04495478 · Eli Lilly and Company
2020-07-30 – 2021-05-09 · Healthy
What this study did
NCT03193918 · Arog Pharmaceuticals, Inc.
2017-04-14 – 2020-07-15 · Esophagogastric Adenocarcinoma
What this study did
NCT02597036 · Eli Lilly and Company
2015-11-06 – 2020-05-24 · Solid Tumors
What this study did
NCT02564198 · Eli Lilly and Company
2015-12-11 – 2019-07-16 · Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies
What this study did
NCT01285037 · Eli Lilly and Company
2009-09-09 – 2017-09-11 · Cancer
What this study did
NCT02359058 · Eli Lilly and Company
2015-02 – 2016-11 · Stomach Neoplasms
What this study did
NCT01682135 · Eli Lilly and Company
2012-11 – 2015-03 · Solid Tumor
What this study did
NCT01256567 · Eli Lilly and Company
2010-12 – 2013-02 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT01286818 · Eli Lilly and Company
2011-02 – 2012-03 · Colorectal Carcinoma
What this study did
NCT01253525 · Eli Lilly and Company
2010-11 – 2011-10 · Adenocarcinoma
What this study did
NCT01005355 · Eli Lilly and Company
2009-09 – 2011-02 · Advanced Solid Tumors
What this study did
NCT00793975 · Eli Lilly and Company
2005-01 – 2009-06 · Advanced Solid Tumors
What this study did
NCT00786383 · Eli Lilly and Company
2006-02 – 2009-01 · Cancer
What this study did
Phase 4 (1)
Gastric Cancer
NCT06169410 · Yang Jianjun, PhD
2023-12-30 – 2025-12-31 · Advanced Gastric Cancer
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT04517747 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2020-10-15 – 2023-01-20 · Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction
What this study did
Used as active comparator (14)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Gastric Cancer
NCT06123494 · Jiangsu HengRui Medicine Co., Ltd.
2024-01-09 – 2027-06-30 · HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06346392 · AstraZeneca
2024-03-04 – 2026-10-14 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT04704934 · Daiichi Sankyo
2021-05-21 – 2026-08-31 · Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Non-Small Cell Lung Cancer
Phase 2/3 (2)
Non-Small Cell Lung Cancer
NCT05096663 · SWOG Cancer Research Network
2022-03-15 – 2027-12-01 · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
Phase 2 (5)
Gastric Cancer
NCT03704077 · Bristol-Myers Squibb
2019-10-31 – 2024-09-30 · Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
What this study did
Non-Small Cell Lung Cancer
NCT07603856 · University of Chicago
2026-12-12 – 2030-06-25 · Non-Small Cell Lung Cancer, Metastatic Lung Cancer
What this study did
NCT04310007 · National Cancer Institute (NCI)
2020-07-13 – 2027-03-31 · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT06904300 · Sun Yat-sen University
2025-08-15 – 2028-12-31 · Gastric (Cardia, Body) Cancer
What this study did
NCT04267913 · SWOG Cancer Research Network
2020-09-05 – 2026-10-31 · Lung Squamous Cell Carcinoma, Recurrent Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03281369 · Hoffmann-La Roche
2017-10-13 – 2025-10-09 · Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT05062980 · Genprex, Inc.
2022-03-30 – 2025-02-03 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT03863587 · Shanghai Henlius Biotech
2019-06-06 – 2019-09-24 · Healthy Male Volunteers
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Other / comorbidity
NCT04499924 · Seagen Inc.
2021-03-22 – 2024-04-17 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ramucirumab: this drugApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
BecotatugPhase 3Monoclonal antibodyEGFRPartial signal
NCT06380348: Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24).
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT04471428: Overall Survival (OS) (Up to approximately 24 months): Atezolizumab + Cabozantinib 10.7 months (95% CI 8.8 to 12.3) vs Docetaxel Monotherapy 10.5 months (95% CI 8.6 to 13) missed
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4Weak signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-APartial signal
NCT03952403: ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC.
IBI305Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT02954172: Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33.
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890
Phase 3(overall)
Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab And TuvonralimabPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAReliable signal
NCT05499390: HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized
NCT05184712: HARMONi-A (NCT05184712), independent-review PFS: ivonescimab plus chemotherapy 7.1 vs placebo plus chemotherapy 4.8 months; HR 0.46 (95% CI 0.34-0.62), P<.001
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT03533127: LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated.
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Retlirafusp AlfaPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signalNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 2Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 2Small moleculeHDACWeak signal
NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
ASP546CPhase 1/2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
BafisontamabPhase 1/2Multispecific antibodyEGFR x c-METWeak signalFeatured results are dose-finding only in this race
BGB-B2033Phase 1/2Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 1/2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 1/2PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 1/2Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Precemtabart TocentecanPhase 1/2Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
AfivastobartPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T CellPhase 1Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
ONO-4578Phase 1Small moleculeProstaglandin E2 receptor 4 (EP4)not yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 108 furthest-along competitors are listed; 502 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(29 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ramucirumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03909334 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03527108 · CT.gov ↗
What to watch
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06043427 · CT.gov ↗
What to watch
2027 (13)
February 2027 (1)
Phase 2Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2027-02-01 · NCT04205968 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Neoplasms, Child, AdolescentRecruiting
Est. primary completion 2027-05 · NCT05999994 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT04999761 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT07669740 · CT.gov ↗
What to watch
Phase 2Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma …Active not recruiting
Est. primary completion 2027-06-30 · NCT05980000 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT05642572 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-30 · NCT06448754 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-08-01 · NCT06251973 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-08-11 · NCT04069273 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-10-31 · NCT06038578 · CT.gov ↗
What to watch
Phase 2/3Gastric CancerRecruiting
Est. primary completion 2027-10-31 · NCT06203600 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2027-12-31 · NCT05927857 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT06616584 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
May 2028 (3)
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2028-05-09 · NCT06445972 · CT.gov ↗
What to watch
Phase 1Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2028-05-31 · NCT05365581 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-05-31 · NCT06031688 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-08-17 · NCT06007937 · CT.gov ↗
What to watch
2029 (5)
January 2029 (1)
Phase 1Gastric CancerRecruiting
Est. primary completion 2029-01-14 · NCT06675136 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-23 · NCT06996782 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-04-06 · NCT07098338 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Gastroesophageal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-09 · NCT07763171 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2029-12-31 · NCT06962137 · CT.gov ↗
What to watch
2030 (3)
January 2030 (1)
Phase 2HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric AdenocarcinomaActive not recruiting
Est. primary completion 2030-01 · NCT07546812 · CT.gov ↗
What to watch
April 2030 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2030-04-30 · NCT05719558 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1Gastric CancerRecruiting
Est. primary completion 2030-09-09 · NCT07594548 · CT.gov ↗
What to watch

See the full readout calendar ↗